Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Daclatasvir. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 7/20 | 0.98 |
| ▸ | CYP2C9 | P11712 | 6/20 | 0.98 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.98 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.98 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.98 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.98 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.87 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.85 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Daclatasvir SCHEMBL2756027 | 0.99 | CYP3A4 (1.00) | CYP3A4CYP2C9KCNH2NR1I2ABCB11 | |
| Daclatasvir SCHEMBL13337981 | 0.99 | CYP3A4 (1.00) | CYP3A4CYP2C9KCNH2NR1I2ABCB11 | |
| Daclatasvir SCHEMBL12175169 | 0.99 | CYP3A4 (1.00) | CYP3A4CYP2C9KCNH2NR1I2ABCB11 | |
| Hydrochloric Acid SCHEMBL15260332 | 0.99 | CYP3A4 (0.96) | CYP3A4CYP2C9KCNH2NR1I2ABCB11 | |
| Daclatasvir SCHEMBL12175016 | 0.99 | CYP3A4 (1.00) | CYP3A4CYP2C9KCNH2NR1I2ABCB11 | |
| Daclatasvir SCHEMBL21531497 | 0.99 | CYP3A4 (1.00) | CYP3A4CYP2C9KCNH2NR1I2ABCB11 | |
| Daclatasvir SCHEMBL21531495 | 0.99 | CYP3A4 (1.00) | CYP3A4CYP2C9KCNH2NR1I2ABCB11 | |
| Daclatasvir SCHEMBL21531496 | 0.99 | CYP3A4 (1.00) | CYP3A4CYP2C9KCNH2NR1I2ABCB11 | |
| Daclatasvir SCHEMBL21531492 | 0.99 | CYP3A4 (1.00) | CYP3A4CYP2C9KCNH2NR1I2ABCB11 | |
| Hydrochloric Acid SCHEMBL15260334 | 0.99 | CYP3A4 (0.96) | CYP3A4CYP2C9KCNH2NR1I2ABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 313 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260041660-A1 | Compositions And Methods for Treating Acute Respiratory Distress Syndrome (ARDS) And Inflammatory Disorders Caused by Corona Viruses and Other Respiratory Pathogens or Agents That Mediate Pulmonary Injury, Inflammation or Acute Respiratory Distress, And Related Compositions and Methods for Treating and Preventing Human SARS Coronavirus Infection, COVID-19 Disease and Related Symptoms | CHANG RICHARD L (US) | 2026-02-12 | — | — | US | claimed |
| EP-4673568-A1 | MICROBIAL BIOMARKERS IN TRANSPLANTATION AND RELATED METHODS | Karius, Inc. (US) | 2026-01-07 | — | — | EP | claimed |
| US-20250121055-A1 | INTERFERON- INDUCING COMPLEXES AND RNA DUPLEXES AND METHODS OF USE | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2025-04-17 | — | — | US | claimed |
| WO-2024182546-A1 | MICROBIAL BIOMARKERS IN TRANSPLANTATION AND RELATED METHODS | KARIUS, INC. (US) | 2024-09-06 | — | — | WO | claimed |
| EP-4395788-A1 | INTERFERON- INDUCING COMPLEXES AND RNA DUPLEXES AND METHODS OF USE | President And Fellows Of Harvard College (US) | 2024-07-10 | — | — | EP | claimed |
| US-20240082202-A1 | Compositions And Methods for Treating Acute Respiratory Distress Syndrome (ARDS) And Inflammatory Disorders Caused by Corona Viruses and Other Respiratory Pathogens or Agents That Mediate Pulmonary Injury, Inflammation or Acute Respiratory Distress, And Related Compositions and Methods for Treating and Preventing Human SARS Coronavirus Infection, COVID-19 Disease and Related Symptoms | CHANG RICHARD L (US) | 2024-03-14 | — | — | US | claimed |
| US-20240075049-A1 | DRUGS, THERAPEUTIC COMBINATIONS AND METHODS FOR PREVENTING VIRAL AND MICROBIAL INFECTIONS AND THEIR SEQUELAE | TOPELIA AUST LTD ACN 652 771 670 (AU) | 2024-03-07 | — | — | US | claimed |
| EP-4304570-A2 | COMPOSITIONS AND METHODS FOR TREATING ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) AND INFLAMMATORY DISORDERS CAUSED BY CORONAVIRUSES | Phor-Med, Inc. (US) | 2024-01-17 | — | — | EP | claimed |
| US-20230405090-A1 | ANTIVIRAL AGENTS | QUANTEC LIMITED (NZ) | 2023-12-21 | — | — | US | claimed |
| CN-116963744-A | Pharmaceutical, therapeutic combination and method for preventing viral and microbial infections and their sequelae | 拓比利亚欧斯特有限公司(ACN 652 771 670) | 2023-10-27 | — | — | CN | claimed |
| WO-2023034278-A1 | INTERFERON- INDUCING COMPLEXES AND RNA DUPLEXES AND METHODS OF USE | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2023-03-09 | — | — | WO | claimed |
| EP-4138832-A1 | PRODUCTS OF MANUFACTURE AND METHODS FOR TREATING, AMELIORATING OR PREVENTING MICROBIAL INFECTIONS | Topelia Aust Limited (AU) | 2023-03-01 | — | — | EP | claimed |
| US-20220323579-A1 | METHODS OF TREATING FULMINANT VIRAL HEPATITIS | UNIV ROCKEFELLER (US) | 2022-10-13 | — | — | US | claimed |
| US-20220296594-A1 | POTENTIATORS OF ANTIMICROBIAL AND/OR ANTIVIRAL AGENTS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2022-09-22 | — | — | US | claimed |
| CN-108732280-B | Method for separating and detecting daclatasvir hydrochloride and optical isomer thereof | 广东东阳光药业有限公司 | 2022-07-08 | — | — | CN | claimed |
| WO-2022126207-A1 | DRUGS, THERAPEUTIC COMBINATIONS AND METHODS FOR PREVENTING VIRAL AND MICROBIAL INFECTIONS AND THEIR SEQUELAE | TOPELIA AUST LIMITED (ACN 652 771 670) (AU) | 2022-06-23 | — | — | WO | claimed |
| WO-2022098247-A1 | ANTIVIRAL AGENTS | QUANTEC LIMITED (NZ) | 2022-05-12 | — | — | WO | claimed |
| WO-2022076742-A1 | METHODS AND COMPOSITIONS FOR TREATING VIRAL INFECTIONS | MAX BioPharma, Inc. (US) | 2022-04-14 | — | — | WO | claimed |
| US-10300044-B2 | Polymorphic forms of methyl((1S)-1-(((2S)-2-(5-(4′-(2-((2S)-1-((2S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)-2-pyrrolidinyl)-1H-imidazol-5-yl)-4-biphenylyl)-1H-imidazol-2-yl)-1-pyrrolidinyl)carbonyl)-2-methylpropyl)carbamate and salts thereof | CIPLA LIMITED (IN) | 2019-05-28 | — | — | US | claimed |
| US-20170354644-A1 | Polymorphic Forms of Methyl((1S)-1-(((2S)-2-(5-(4'-(2-((2S)-1-((2S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)-2-pyrrolidinyl)-1H-imidazol-5-yl)-4-biphenylyl)-1H-imidazol-2-yl)-1-pyrrolidinyl) carbonyl)-2-methylpropyl)carbamate and Salts Thereof | CIPLA LIMITED (IN) | 2017-12-14 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240075049-A1 | DRUGS, THERAPEUTIC COMBINATIONS AND METHODS FOR PREVENTING VIRAL AND MICROBIAL INFECTIONS AND THEIR SEQUELAE | ACE, ACHE, SARS1 | CYP3A4 828/4885CYP2C9 1776/4885KCNH2 3661/4885 |
| US-20220296594-A1 | POTENTIATORS OF ANTIMICROBIAL AND/OR ANTIVIRAL AGENTS | MAVS, IRF3, STING1 | CYP3A4 3306/4885CYP2C9 4357/4885KCNH2 4313/4885 |
| US-10300044-B2 | Polymorphic forms of methyl((1S)-1-(((2S)-2-(5-(4′-(2-((2S)-1-((2S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)-2-pyrrolidinyl)-1H-imidazol-5-yl)-4-biphenylyl)-1H-imidazol-2-yl)-1-pyrrolidinyl)carbonyl)-2-methylpropyl)carbamate and salts thereof | MECP2, MAT2A, CPS1 | CYP3A4 128/4885CYP2C9 297/4885KCNH2 498/4885 |
| US-20260041660-A1 | Compositions And Methods for Treating Acute Respiratory Distress Syndrome (ARDS) And Inflammatory Disorders Caused by Corona Viruses and Other Respiratory Pathogens or Agents That Mediate Pulmonary Injury, Inflammation or Acute Respiratory Distress, And Related Compositions and Methods for Treating and Preventing Human SARS Coronavirus Infection, COVID-19 Disease and Related Symptoms | TSLP, MAVS, PLAA | CYP3A4 3902/4885CYP2C9 4129/4885KCNH2 4021/4885 |
| US-20170354644-A1 | Polymorphic Forms of Methyl((1S)-1-(((2S)-2-(5-(4'-(2-((2S)-1-((2S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)-2-pyrrolidinyl)-1H-imidazol-5-yl)-4-biphenylyl)-1H-imidazol-2-yl)-1-pyrrolidinyl) carbonyl)-2-methylpropyl)carbamate and Salts Thereof | MECP2, CPS1, MAT2A | CYP3A4 133/4885CYP2C9 303/4885KCNH2 499/4885 |
| US-20240082202-A1 | Compositions And Methods for Treating Acute Respiratory Distress Syndrome (ARDS) And Inflammatory Disorders Caused by Corona Viruses and Other Respiratory Pathogens or Agents That Mediate Pulmonary Injury, Inflammation or Acute Respiratory Distress, And Related Compositions and Methods for Treating and Preventing Human SARS Coronavirus Infection, COVID-19 Disease and Related Symptoms | MAVS, ACE2, PLAA | CYP3A4 4354/4885CYP2C9 4672/4885KCNH2 3365/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.